Evidence map›Paper›PMID 41519959›Full record

ArticleScientific reports2026

Prior pulmonary tuberculosis deteriorated all-cause mortality in AECOPD patients after discharge.

Ruoyan Xiong, Zhiqi Zhao, Yanan Cui, Weiwei Meng, Jiayu Wang, Rui Zhao, Jiankang Wu, Huihui Zeng, Yan Chen

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruoyan Xiong *Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhiqi Zhao *Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yanan CuiDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Weiwei MengDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiayu WangDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Rui ZhaoDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiankang WuDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huihui ZengDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. bonemarrow@csu.edu.cn.
Yan ChenDepartment of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. chenyan99727@csu.edu.cn.

Funding

Natural Science Foundation of Hunan Province 2023JJ30742
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) patients who have a history of pulmonary tuberculosis (PTB) often present with worse dyspnea and more acute exacerbations (AEs). However, the impact of prior PTB on prognosis in AECOPD patients remains to be further investigated. The diagnosis of patients with prior PTB was based on a combination of imaging and prior tuberculosis history. This study compared the clinical characteristics and prognosis of the Chinese AECOPD inpatients with or without prior PTB, and discussed the role of glucocorticoids in the prognosis of AECOPD patients with prior PTB by Kaplan-Meier analysis and Cox Regression analysis. 740 inpatients enrolled, and 231 patients (31.2%) were considered as the PTB group. The PTB group had obviously higher 1-year mortality (19.4% vs. 10.7%, P = 0.003) and long-term mortality (47.6% vs. 33.3%, P = 0.001) after discharge. Moreover, discharged AECOPD patients were defined as group E in the stable stage, and these group E patients with prior PTB using inhaled corticosteroid (ICS) during the stable stage were found to have lower mortality than those who did not use ICS after discharge. The predictors of ICS use decreasing all-cause mortality among these E group patients with PTB included patient characteristics, and CAT ≥ 20 was the strongest predictor (HR, 0.043; 95% CI, 0.006-0.331; P < 0.01). In this study, more than 30% of AECOPD patients had prior PTB, and the mortality of discharged AECOPD patients with prior PTB was significantly greater than that of those without. Surprisingly, ICS use during the stable stage appears to be associated with improved survival in discharged AECOPD patients who had prior PTB, and the strongest predictors of the association were CAT ≥ 20.

Indexed as

Pulmonary Disease, Chronic ObstructiveTuberculosis, PulmonaryAdrenal Cortex HormonesAgedDisease ProgressionFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPatient DischargePrognosisProportional Hazards ModelsAdrenal Cortex Hormones

Identifiers

PMID41519959
PMCPMC12877004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.